All In Biotech

Drug Trial Radar · NCT03181984

Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain

Last checked: Nov 19, 2026Latest source record: Dec 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

501

Actual

Start

Aug 31, 2017

Primary completion

Apr 19, 2023

Study completion Apr 19, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine drug uses.

Conditions

  • Port-Wine Stain

Interventions

  • HemoporfinDrug

    Hemoporfin mediated photodynamic therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse eventsTime frame: 96 weeks after hemoporfin application

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China

  • PLA Army General Hospital

    Beijing, China

  • Shanghai Dermatology Hospital

    Shanghai, China

  • The 2nd Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Affiliated Hospital of Hebei Medical College of traditional Chinese Medicine

    Shijiazhuang, Herbei, China

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.